Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
WEGOVY (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity: To reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight
"*" indicates required fields Editorial Policy: Science-Backed, Expert-Reviewed The Edge upholds the highest standards of health journalism
Severe or multisystem metabolic disease: Significant obesity plus diabetes, MASLD, OSA, or clustered cardiovascular risk factors, where every extra few percentage points of weight and risk reduction matter. Patients who need maximum, not moderate, change: Those aiming for 20%plus loss to qualify for surgery, offload joints, or defuse highstakes diagnoses in a defined time window. Patients who can handle tighter structure: People willing to tolerate stronger appetite suppression, closer titration, and more lab and nutrition oversight in exchange for bigger, faster shifts in body weight and cardiometabolic markers. Who leans toward semaglutide
More commonly tied to cagrilintide than tirzepatide
Dehydration and reduced appetite, make it hard to consume enough calories
US$ 21.60
US$ 26.04
US$ 27.78
US$ 26.88
